Home The Word Brain Fast Track My Amedeo FAQ About Flying Publisher   

Fast Track

Ear2MemoryFree App | Free PDF | Web
Learning languages on your smartphone
By BSK

Free Abstracts

  Prostate Cancer

  Free Subscription


Articles published in J Urol

Retrieve available abstracts of 318 articles:
HTML format
Text format



Single Articles


    October 2017
  1. ATALA A
    Re: Genome-Wide Association Study of Prostate-Specific Antigen Levels Identifies Novel Loci Independent of Prostate Cancer.
    J Urol. 2017;198:747.
    PubMed     Text format    


  2. TANEJA SS
    Re: Presence of Invasive Cribriform or Intraductal Growth at Biopsy Outperforms Percentage Grade 4 in Predicting Outcome of Gleason Score 3+4=7 Prostate Cancer.
    J Urol. 2017;198:745.
    PubMed     Text format    


  3. PENSON DF
    Re: Association between Radiation Therapy, Surgery, or Observation for Localized Prostate Cancer and Patient-Reported Outcomes after 3 Years.
    J Urol. 2017;198:744-745.
    PubMed     Text format    


  4. TANEJA SS
    Re: Association between Radiation Therapy, Surgery, or Observation for Localized Prostate Cancer and Patient-Reported Outcomes after 3 Years.
    J Urol. 2017;198:743-744.
    PubMed     Text format    


  5. TANEJA SS
    Re: Germline Mutations in ATM and BRCA1/2 Distinguish Risk for Lethal and Indolent Prostate Cancer and are Associated with Early Age at Death.
    J Urol. 2017;198:742-743.
    PubMed     Text format    


  6. TANEJA SS
    Re: Active Surveillance in Younger Men with Prostate Cancer.
    J Urol. 2017;198:741-745.
    PubMed     Text format    


  7. PENSON DF
    Re: Sharp Decline in Prostate Cancer Treatment among Men in the General Population, but Not among Diagnosed Men.
    J Urol. 2017;198:734-735.
    PubMed     Text format    


  8. GRIEBLING TL
    Re: Current Impact of Age and Comorbidity Assessment on Prostate Cancer Treatment Choice and Over/Undertreatment Risk.
    J Urol. 2017;198:724.
    PubMed     Text format    


  9. GRIEBLING TL
    Re: Comorbidity and Age Cannot Explain Variation in Life Expectancy Associated with Treatment of Non-Metastatic Prostate Cancer.
    J Urol. 2017;198:723.
    PubMed     Text format    


  10. GRIEBLING TL
    Re: Which Better Predicts Mortality among Older Men, a Prostate Cancer (PCa) Diagnosis or Vulnerability on the Vulnerable Elders Survey (VES-13)? A Retrospective Cohort Study.
    J Urol. 2017;198:723-724.
    PubMed     Text format    


    September 2017
  11. NEHRA A, Parker WP, Haloi R, Park SS, et al
    Identification of Recurrence Sites Following Post-Prostatectomy Treatment for Prostate Cancer Using 11C-Choline Positron Emission Tomography and Multiparametric Pelvic MRI.
    J Urol. 2017 Sep 12. pii: S0022-5347(17)77497-6. doi: 10.1016/j.juro.2017.
    PubMed     Text format     Abstract available


  12. ORCZYK C, Emberton M
    Re: Magnetic Resonance Imaging Underestimation of Prostate Cancer Geometry: Use of Patient Specific Molds to Correlate Images with Whole Mount Pathology: A. Priester, S. Natarajan, P. Khoshnoodi, D. J. Margolis, S. S. Raman, R. E. Reiter, J. Huang, W.
    J Urol. 2017 Sep 6. pii: S0022-5347(17)77256-4. doi: 10.1016/j.juro.2017.
    PubMed     Text format    


  13. ATALA A
    Re: MicroRNA-141 Suppresses Prostate Cancer Stem Cells and Metastasis by Targeting a Cohort of Pro-Metastasis Genes.
    J Urol. 2017;198:486.
    PubMed     Text format    


  14. ATALA A
    Re: AKT-Mediated Stabilization of Histone Methyltransferase WHSC1 Promotes Prostate Cancer Metastasis.
    J Urol. 2017;198:485-487.
    PubMed     Text format    


  15. TANEJA SS
    Re: Videotaping of Surgical Procedures and Outcomes following Extraperitoneal Laparoscopic Radical Prostatectomy for Clinically Localized Prostate Cancer.
    J Urol. 2017;198:483-484.
    PubMed     Text format    


  16. SEFTEL AD
    Re: Association between Radiation Therapy, Surgery, or Observation for Localized Prostate Cancer and Patient-Reported Outcomes after 3 Years.
    J Urol. 2017;198:466-468.
    PubMed     Text format    


  17. TEETER AE, Griffin K, Howard LE, Aronson WJ, et al
    Does early PSADT (ePSADT) after Radical Prostatectomy, Calculated prior to PSA Recurrence, Correlate with Prostate Cancer Outcomes? -A Report from the SEARCH Database Group.
    J Urol. 2017 Sep 1. pii: S0022-5347(17)77427-7. doi: 10.1016/j.juro.2017.
    PubMed     Text format     Abstract available


    August 2017
  18. TOMBAL B, Borre M, Rathenborg P, Werbrouck P, et al
    Long-term Anti-tumor Activity and Safety of Enzalutamide Monotherapy in Hormone-naive Prostate Cancer: 3-year, Open-label, Follow-up Results.
    J Urol. 2017 Aug 31. pii: S0022-5347(17)77422-8. doi: 10.1016/j.juro.2017.
    PubMed     Text format     Abstract available


  19. CASTELLO A, Boldo E, Amiano P, Castano-Vinyals G, et al
    Mediterranean dietary pattern is associated to low risk of aggressive prostate cancer: MCC-Spain study.
    J Urol. 2017 Aug 22. pii: S0022-5347(17)77385-5. doi: 10.1016/j.juro.2017.
    PubMed     Text format     Abstract available


  20. SIEMENS DR, Klotz L, Heidenreich A, Chowdhury S, et al
    Efficacy and Safety of Enzalutamide vs Bicalutamide in Younger and Older Patients with Metastatic Castration-resistant Prostate Cancer in the TERRAIN Trial.
    J Urol. 2017 Aug 18. pii: S0022-5347(17)77377-6. doi: 10.1016/j.juro.2017.
    PubMed     Text format     Abstract available


  21. GARCIA-BARRERAS S, Sanchez-Salas R, Sivaraman A, Barret E, et al
    Partial gland ablation versus radical prostatectomy Comparative Analysis of Partial Gland Ablation and Radical Prostatectomy to Treat Low- and Intermediate-risk Prostate Cancer: Oncologic and Functional Outcomes.
    J Urol. 2017 Aug 17. pii: S0022-5347(17)77373-9. doi: 10.1016/j.juro.2017.
    PubMed     Text format     Abstract available


  22. SHRESTHA E, White JR, Yu SH, Kulac I, et al
    Profiling the Urinary Microbiome in Men with Positive versus Negative Biopsies for Prostate Cancer.
    J Urol. 2017 Aug 7. pii: S0022-5347(17)77253-9. doi: 10.1016/j.juro.2017.
    PubMed     Text format     Abstract available


  23. DAI C, Ganesan V, Zabell J, Nyame YA, et al
    Impact of 5alpha-reductase inhibitors on disease reclassification among men on active surveillance for localized prostate cancer with favorable features.
    J Urol. 2017 Aug 5. pii: S0022-5347(17)77259-X. doi: 10.1016/j.juro.2017.
    PubMed     Text format     Abstract available


  24. AUFFENBERG GB, Lane BR, Linsell S, Brachulis A, et al
    A Roadmap for improving the management of men with favorable-risk prostate cancer.
    J Urol. 2017 Aug 3. pii: S0022-5347(17)77250-3. doi: 10.1016/j.juro.2017.
    PubMed     Text format    


    July 2017
  25. SAMMON JD, Serrell EC, Karabon P, Leow JJ, et al
    Prostate Cancer Screening in Early Medicaid Expansion States.
    J Urol. 2017 Jul 29. pii: S0022-5347(17)77241-2. doi: 10.1016/j.juro.2017.
    PubMed     Text format     Abstract available


  26. TAPLIN ME, Armstrong AJ, Lin P, Krivoshik A, et al
    Clinical Outcomes of Chemotherapy-Naive Men with Metastatic Castration-Resistant Prostate Cancer and Low Baseline PSA Treated with Enzalutamide vs Placebo.
    J Urol. 2017 Jul 20. pii: S0022-5347(17)77187-X. doi: 10.1016/j.juro.2017.
    PubMed     Text format     Abstract available


  27. TAMMELA TL, Haggman M, Ladjevardi S, Taari K, et al
    An Intraprostatic Modified Release Formulation of Antiandrogen 2-Hydroxyflutamide for Localized Prostate Cancer.
    J Urol. 2017 Jul 20. pii: S0022-5347(17)77188-1. doi: 10.1016/j.juro.2017.
    PubMed     Text format     Abstract available


  28. GORIN MA, Rowe SP, Patel HD, Vidal I, et al
    PSMA-targeted 18F-DCFPyL PET/CT in the Preoperative Staging of Men with High-risk Prostate Cancer: Results of a Prospective Phase II Single-Center Study.
    J Urol. 2017 Jul 20. pii: S0022-5347(17)77186-8. doi: 10.1016/j.juro.2017.
    PubMed     Text format     Abstract available


  29. CHANG E, Jones TA, Natarajan S, Sharma D, et al
    Value of Tracking Biopsy in Men Undergoing Active Surveillance of Prostate Cancer.
    J Urol. 2017 Jul 17. pii: S0022-5347(17)77144-3. doi: 10.1016/j.juro.2017.
    PubMed     Text format     Abstract available


  30. YANG L, Kibel AS, Colditz GA, Pakpahan R, et al
    Caution with Use of the Expanded Prostate Cancer Index Composite-50 Urinary Bother Scale: How Voiding Dysfunction Modifies Its Performance.
    J Urol. 2017 Jul 17. pii: S0022-5347(17)77147-9. doi: 10.1016/j.juro.2017.
    PubMed     Text format     Abstract available


  31. STROUP SP, Moreira DM, Chen Z, Howard L, et al
    Biopsy-Detected Gleason Pattern 5 is Associated with Recurrence, Metastasis, and Mortality in a Cohort of Men with High-Risk Prostate Cancer.
    J Urol. 2017 Jul 11. pii: S0022-5347(17)77098-X. doi: 10.1016/j.juro.2017.
    PubMed     Text format     Abstract available


  32. PENSON DF
    Re: Increase in Prostate Cancer Distant Metastases at Diagnosis in the United States.
    J Urol. 2017;198:104-105.
    PubMed     Text format    


  33. PENSON DF
    Re: Vasectomy and Prostate Cancer Incidence and Mortality in a Large US Cohort.
    J Urol. 2017;198:104-106.
    PubMed     Text format    


  34. ATALA A
    Re: Targeted Molecular-Genetic Imaging and Ligand-Directed Therapy in Aggressive Variant Prostate Cancer.
    J Urol. 2017;198:103-104.
    PubMed     Text format    


  35. ATALA A
    Re: Low CD38 Identifies Progenitor-Like Inflammation-Associated Luminal Cells that Can Initiate Human Prostate Cancer and Predict Poor Outcome.
    J Urol. 2017;198:103.
    PubMed     Text format    


  36. ATALA A
    Re: Rb1 and Trp53 Cooperate to Suppress Prostate Cancer Lineage Plasticity, Metastasis, and Antiandrogen Resistance.
    J Urol. 2017;198:102-104.
    PubMed     Text format    


  37. TANEJA SS
    Re: Diagnostic Accuracy of Multi-Parametric MRI and TRUS Biopsy in Prostate Cancer (PROMIS): A Paired Validating Confirmatory Study.
    J Urol. 2017;198:101-102.
    PubMed     Text format    


  38. TANEJA SS
    Re: Radiation with or without Antiandrogen Therapy in Recurrent Prostate Cancer.
    J Urol. 2017;198:100-102.
    PubMed     Text format    


    June 2017
  39. BHINDI B, Karnes RJ, Rangel LJ, Mason RJ, et al
    Independent Validation of the American Joint Committee on Cancer 8th Edition Prostate Cancer Staging Classification.
    J Urol. 2017 Jun 29. pii: S0022-5347(17)77027-9. doi: 10.1016/j.juro.2017.
    PubMed     Text format     Abstract available


  40. JONES TA, Chin J, Mcleod D, Barkin J, et al
    High-Intensity Focused Ultrasound for Radio-recurrent Prostate Cancer: A North American Clinical Trial.
    J Urol. 2017 Jun 23. pii: S0022-5347(17)76734-1. doi: 10.1016/j.juro.2017.
    PubMed     Text format     Abstract available


  41. PALAPATTU GS
    Genomic Tests Should be Used to Help Guide Treatment of Prostate Cancer: Yes.
    J Urol. 2017 Jun 16. pii: S0022-5347(17)67196-9. doi: 10.1016/j.juro.2017.
    PubMed     Text format    


  42. PUNNEN S, Parekh DJ
    Genomic Tests Should be Used to Help Guide Treatment of Prostate Cancer: No.
    J Urol. 2017 Jun 16. pii: S0022-5347(17)67197-0. doi: 10.1016/j.juro.2017.
    PubMed     Text format    


  43. KIBEL AS
    Intermediate Risk Prostate Cancer and Active Surveillance: Maximize Utilization while Minimizing Failure.
    J Urol. 2017 Jun 16. pii: S0022-5347(17)74842-2. doi: 10.1016/j.juro.2017.
    PubMed     Text format    


  44. SEFTEL AD
    Re: Rasch Analysis of the Premature Ejaculation Diagnostic Tool (PEDT) and the International Index of Erectile Function (IIEF) in an Iranian Sample of Prostate Cancer Patients.
    J Urol. 2017;197:1534-1535.
    PubMed     Text format    


  45. KAPLAN SA
    Re: Interactions between Benign Prostatic Hyperplasia (BPH) and Prostate Cancer in Large Prostates: A Retrospective Data Review.
    J Urol. 2017;197:1531-1532.
    PubMed     Text format    


  46. ATALA A
    Re: Androgen Receptor Antagonists Compromise T Cell Response against Prostate Cancer Leading to Early Tumor Relapse.
    J Urol. 2017;197:1459.
    PubMed     Text format    


  47. ATALA A
    Re: Activation of Notch1 Synergizes with Multiple Pathways in Promoting Castration-Resistant Prostate Cancer.
    J Urol. 2017;197:1458-1459.
    PubMed     Text format    


  48. CADEDDU JA
    Re: Magnetic Resonance Imaging-Guided Transurethral Ultrasound Ablation of Prostate Tissue in Patients with Localized Prostate Cancer: A Prospective Phase 1 Clinical Trial.
    J Urol. 2017;197:1457-1458.
    PubMed     Text format    


  49. TANEJA SS
    Re: Urologist-Level Correlation in the Use of Observation for Low- and High-Risk Prostate Cancer.
    J Urol. 2017;197:1456.
    PubMed     Text format    


  50. TANEJA SS
    Re: Mortality among Men with Advanced Prostate Cancer Excluded from the ProtecT Trial.
    J Urol. 2017;197:1456-1457.
    PubMed     Text format    


  51. DENIZE J, Nouhaud FX, Cornu JN, Pfister C, et al
    Re: Timing of Adverse Prostate Cancer Reclassification on First Surveillance Biopsy: Results from the Canary Prostate Cancer Active Surveillance Study: L. C. Macleod, W. J. Ellis, L. F. Newcomb, Y. Zheng, J. D. Brooks, P. R. Carroll, M. E. Gleave, R.
    J Urol. 2017 Jun 1. pii: S0022-5347(17)59378-7. doi: 10.1016/j.juro.2017.
    PubMed     Text format    


    May 2017
  52. YAN W, Shang Z, Zhou Z
    Re: Magnetic Resonance Imaging Underestimation of Prostate Cancer Geometry: Use of Patient Specific Molds to Correlate Images with Whole Mount Pathology: A. Priester, S. Natarajan, P. Khoshnoodi, D. J. Margolis, S. S. Raman, R. E. Reiter, J. Huang, W.
    J Urol. 2017 May 31. pii: S0022-5347(17)57834-9. doi: 10.1016/j.juro.2017.
    PubMed     Text format    


  53. TELOKEN PE, Li J, Woods CG, Cohen RJ, et al
    The impact of prostate cancer zonal origin on pathological parameters at radical prostatectomy and subsequent biochemical failure.
    J Urol. 2017 May 26. pii: S0022-5347(17)74541-7. doi: 10.1016/j.juro.2017.
    PubMed     Text format     Abstract available


  54. TOMBAL B, Cornel EB, Persad R, Stari A, et al
    Clinical Outcomes and Testosterone Levels Following Continuous Androgen Deprivation in Patients with Relapsing or Locally Advanced Prostate Cancer: A Post Hoc Analysis of the ICELAND Study.
    J Urol. 2017 May 25. pii: S0022-5347(17)74503-X. doi: 10.1016/j.juro.2017.
    PubMed     Text format     Abstract available


  55. FELDMAN AS, Meyer CP, Sanchez A, Krasnova A, et al
    Morbidity and Mortality of Locally Advanced Prostate Cancer: A Population-Based Analysis Comparing Radical Prostatectomy Versus External Beam Radiation.
    J Urol. 2017 May 25. pii: S0022-5347(17)74504-1. doi: 10.1016/j.juro.2017.
    PubMed     Text format     Abstract available


  56. LEE DJ, Mallin K, Graves AJ, Chang SS, et al
    Recent changes in prostate cancer screening practices and prostate cancer epidemiology.
    J Urol. 2017 May 25. pii: S0022-5347(17)74517-X. doi: 10.1016/j.juro.2017.
    PubMed     Text format     Abstract available


  57. HENRY MA, Howard DH, Davies BJ, Filson CP, et al
    Variation in Use of Prostate Biopsy Following Changes in Prostate Cancer Screening Guidelines.
    J Urol. 2017 May 6. pii: S0022-5347(17)64683-4. doi: 10.1016/j.juro.2017.
    PubMed     Text format     Abstract available


    April 2017
  58. GOLAN R, Bernstein AN, McClure TD, Sedrakyan A, et al
    Partial gland treatment of prostate cancer utilizing high-intensity focused ultrasound in the primary and salvage setting: a systematic review.
    J Urol. 2017 Apr 19. pii: S0022-5347(17)54786-2. doi: 10.1016/j.juro.2017.
    PubMed     Text format     Abstract available


  59. NATARAJAN S, Jones TA, Priester AM, Geoghegan R, et al
    Focal Laser Ablation of Prostate Cancer: Feasibility of MRI/US Fusion for Guidance.
    J Urol. 2017 Apr 7. pii: S0022-5347(17)45433-4. doi: 10.1016/j.juro.2017.
    PubMed     Text format     Abstract available


    March 2017
  60. DISTLER FA, Radtke JP, Bonekamp D, Kesch C, et al
    The value of PSA density in combination with PI-RADS for the accuracy of prostate cancer prediction.
    J Urol. 2017 Mar 31. pii: S0022-5347(17)43846-8. doi: 10.1016/j.juro.2017.
    PubMed     Text format     Abstract available


  61. MEHRALIVAND S, Bednarova S, Shih JH, Mertan FV, et al
    Prospective Evaluation of Prostate Imaging-Reporting and Data System Version 2 Using the International Society of Urological Pathology Prostate Cancer Grade Group System.
    J Urol. 2017 Mar 31. pii: S0022-5347(17)43847-X. doi: 10.1016/j.juro.2017.
    PubMed     Text format     Abstract available


  62. NYAME YA, Almassi N, Haywood SC, Greene DJ, et al
    Intermediate-Term Outcomes of Men with Very Low/Low and Intermediate/High Risk Prostate Cancer Managed by Active Surveillance.
    J Urol. 2017 Mar 24. pii: S0022-5347(17)42185-9. doi: 10.1016/j.juro.2017.
    PubMed     Text format     Abstract available


  63. LEBDAI S, Bigot P, Leroux PA, Berthelot LP, et al
    Vascular-Targeted Photodynamic Therapy with Padeliporfin for Low Risk Prostate Cancer Treatment: Mid-Term Oncological Outcomes.
    J Urol. 2017 Mar 18. pii: S0022-5347(17)40346-6. doi: 10.1016/j.juro.2017.
    PubMed     Text format     Abstract available


  64. PENSON DF
    Re: Active Surveillance of Prostate Cancer in a Community Practice: How to Measure, Manage, and Improve?
    J Urol. 2017;197.
    PubMed     Text format    


  65. PENSON DF
    Re: Association of Androgen Deprivation Therapy with Depression in Localized Prostate Cancer.
    J Urol. 2017;197.
    PubMed     Text format    


  66. PENSON DF
    Re: Patient-Reported Outcomes after Monitoring, Surgery, or Radiotherapy for Prostate Cancer.
    J Urol. 2017;197.
    PubMed     Text format    


  67. ATALA A
    Re: Integrative Analyses Reveal a Long Noncoding RNA-Mediated Sponge Regulatory Network in Prostate Cancer.
    J Urol. 2017;197.
    PubMed     Text format    


  68. ATALA A
    Re: Integrated Classification of Prostate Cancer Reveals a Novel Luminal Subtype with Poor Outcome.
    J Urol. 2017;197.
    PubMed     Text format    


  69. ATALA A
    Re: Activation of Notch1 Synergizes with Multiple Pathways in Promoting Castration-Resistant Prostate Cancer.
    J Urol. 2017;197.
    PubMed     Text format    


  70. TANEJA SS
    Re: Quantified Clinical Risk Change as an End Point during Prostate Cancer Active Surveillance.
    J Urol. 2017;197.
    PubMed     Text format    


  71. TANEJA SS
    Re: Genomic Alterations in Cell-Free DNA and Enzalutamide Resistance in Castration-Resistant Prostate Cancer.
    J Urol. 2017;197.
    PubMed     Text format    


    February 2017
  72. BOESEN L, Norgaard N, Logager V, Thomsen HS, et al
    Clinical outcome following a low-suspicion multiparametric prostate MRI or benign MRI-guided biopsy to detect prostate cancer: A follow-up study in men with prior negative transrectal ultrasound-guided biopsies.
    J Urol. 2017 Feb 21. pii: S0022-5347(17)30297-5. doi: 10.1016/j.juro.2017.
    PubMed     Text format     Abstract available


  73. HIGANO CS
    The Role of Intermittent Androgen Deprivation Therapy for Prostate Cancer.
    J Urol. 2017 Feb 20. pii: S0022-5347(17)30286-0. doi: 10.1016/j.juro.2017.
    PubMed     Text format    


  74. POMPE RS, Karakiewicz PI, Tian Z, Mandel P, et al
    Oncological and functional outcomes after radical prostatectomy for high or very high-risk prostate cancer - European validation of the current NCCN guideline.
    J Urol. 2017 Feb 16. pii: S0022-5347(17)30291-4. doi: 10.1016/j.juro.2017.
    PubMed     Text format     Abstract available


  75. MURTOLA TJ, Virkku A, Talala K, Stenman UH, et al
    Outcomes of prostate cancer screening by 5-alpha reductase inhibitor usage.
    J Urol. 2017 Feb 16. pii: S0022-5347(17)30290-2. doi: 10.1016/j.juro.2017.
    PubMed     Text format     Abstract available


  76. TRUONG M, Hollenberg G, Weinberg E, Messing EM, et al
    Impact of Gleason Subtype on Prostate Cancer Detection Using Multiparametric MRI: Correlation with Final Histopathology.
    J Urol. 2017 Feb 2. pii: S0022-5347(17)30197-0. doi: 10.1016/j.juro.2017.
    PubMed     Text format     Abstract available


  77. ATALA A
    Re: Inhibition of the Hexosamine Biosynthetic Pathway Promotes Castration-Resistant Prostate Cancer.
    J Urol. 2017;197:403.
    PubMed     Text format    


  78. ATALA A
    Re: The Metabolic Co-Regulator PGC1alpha Suppresses Prostate Cancer Metastasis.
    J Urol. 2017;197:402-403.
    PubMed     Text format    


  79. PENSON DF
    Re: Urologist-Level Correlation in the Use of Observation for Low- and High-Risk Prostate Cancer.
    J Urol. 2017;197:401-402.
    PubMed     Text format    


  80. TANEJA SS
    Re: Magnetic Resonance Imaging-Ultrasound Fusion Biopsy during Prostate Cancer Active Surveillance.
    J Urol. 2017;197:400-401.
    PubMed     Text format    


  81. TANEJA SS
    Re: Inherited DNA-Repair Gene Mutations in Men with Metastatic Prostate Cancer.
    J Urol. 2017;197:399-400.
    PubMed     Text format    


  82. TANEJA SS
    Re: Study of Testosterone-Guided Androgen Deprivation Therapy in Management of Prostate Cancer.
    J Urol. 2017;197:398-399.
    PubMed     Text format    


  83. TANEJA SS
    Re: Predictive Parameters of Symptomatic Hematochezia following 5-Fraction Gantry-Based SABR in Prostate Cancer.
    J Urol. 2017;197:398-401.
    PubMed     Text format    


  84. JEONG IG, Yoo S, Lee C, Kim M, et al
    Obesity as a Risk Factor for Unfavorable Disease in Low-risk Prostate Cancer and Its Relationship with Anatomic Location of Tumor.
    J Urol. 2017 Feb 1. pii: S0022-5347(17)30193-3. doi: 10.1016/j.juro.2017.
    PubMed     Text format     Abstract available


    January 2017
  85. BHINDI B, Rangel LJ, Mason RJ, Gettman MT, et al
    Impact of Radical Prostatectomy on Long-Term Oncologic Outcomes in a Matched-Cohort of Men with Pathologic Node-Positive Prostate Cancer Managed with Castration.
    J Urol. 2017 Jan 24. pii: S0022-5347(17)30089-7. doi: 10.1016/j.juro.2017.
    PubMed     Text format     Abstract available


  86. PRENDEVILLE S, Nesbitt ME, Evans AJ, Fleshner NE, et al
    Variant Histology and Clinicopathologic Features of Prostate Cancer in Men Aged <50 Years Treated with Radical Prostatectomy.
    J Urol. 2017 Jan 24. pii: S0022-5347(17)30087-3. doi: 10.1016/j.juro.2017.
    PubMed     Text format     Abstract available


  87. KILPELAINEN TP, Pogodin-Hannolainen D, Kemppainen K, Talala K, et al
    Estimate of opportunistic prostate-specific antigen testing in the Finnish Randomized Study of Screening for Prostate Cancer.
    J Urol. 2017 Jan 16. pii: S0022-5347(17)30074-5. doi: 10.1016/j.juro.2017.
    PubMed     Text format     Abstract available


  88. GRIEBLING TL
    Re: First-Line Treatment in Senior Adults with Metastatic Castration-Resistant Prostate Cancer: A Prospective International Registry.
    J Urol. 2017;197:157.
    PubMed     Text format    


  89. GRIEBLING TL
    Re: Survival after Conservative Management versus External Beam Radiation Therapy in Elderly Patients with Localized Prostate Cancer.
    J Urol. 2017;197:157-158.
    PubMed     Text format    


  90. GRIEBLING TL
    Re: Clinical Outcomes in Octogenarians Treated with Docetaxel as First-Line Chemotherapy for Castration-Resistant Prostate Cancer.
    J Urol. 2017;197:155-156.
    PubMed     Text format    


  91. GRIEBLING TL
    Re: Trends in Prostate Cancer in Elderly in Denmark, 1980-2012.
    J Urol. 2017;197:155-158.
    PubMed     Text format    


  92. ATALA A
    Re: Resistance to Docetaxel in Prostate Cancer is Associated with Androgen Receptor Activation and Loss of KDM5D Expression.
    J Urol. 2017;197:154-155.
    PubMed     Text format    


  93. PENSON DF
    Re: A Comparison of Web-Based versus Print-Based Decision Aids for Prostate Cancer Screening: Participants' Evaluation and Utilization.
    J Urol. 2017;197:154.
    PubMed     Text format    


  94. PENSON DF
    Re: Treatment Preferences for Active Surveillance versus Active Treatment among Men with Low-Risk Prostate Cancer.
    J Urol. 2017;197:153-154.
    PubMed     Text format    


  95. SIEGEL C
    Re: Can Radiologic Staging with Multiparametric MRI Enhance the Accuracy of the Partin Tables in Predicting Organ-Confined Prostate Cancer?
    J Urol. 2017;197:152-153.
    PubMed     Text format    


  96. TANEJA SS
    Re: Efficacy and Safety of Enzalutamide versus Bicalutamide for Patients with Metastatic Prostate Cancer (TERRAIN): A Randomised, Double-Blind, Phase 2 Study.
    J Urol. 2017;197:152.
    PubMed     Text format    


  97. TANEJA SS
    Re: HSD3B1 and Resistance to Androgen-Deprivation Therapy in Prostate Cancer: A Retrospective, Multicohort Study.
    J Urol. 2017;197:150.
    PubMed     Text format    


  98. TANEJA SS
    Re: Five-Year Biochemical Results, Toxicity, and Patient-Reported Quality of Life after Delivery of Dose-Escalated Image Guided Proton Therapy for Prostate Cancer.
    J Urol. 2017;197:149-152.
    PubMed     Text format    


    December 2016
  99. CATALONA WJ, Richie JP, Ahmann FR, Hudson MA, et al
    Comparison of Digital Rectal Examination and Serum Prostate Specific Antigen in the Early Detection of Prostate Cancer: Results of a Multicenter Clinical: Trial of 6,630 Men.
    J Urol. 2016 Dec 21. pii: S0022-5347(16)31617-2. doi: 10.1016/j.juro.2016.
    PubMed     Text format     Abstract available


  100. LEPOR H
    Surgical Treatment of Prostate Carcinoma.
    J Urol. 2016 Dec 20. pii: S0022-5347(16)31628-7. doi: 10.1016/j.juro.2016.
    PubMed     Text format    


  101. MOUL JW
    Comparison of DRE and PSA in the Detection of Prostate Cancer.
    J Urol. 2016 Dec 20. pii: S0022-5347(16)31725-6. doi: 10.1016/j.juro.2016.
    PubMed     Text format    


  102. HANSEL DE
    The Gleason Grading System: The Approach that Changed Prostate Cancer Assessment.
    J Urol. 2016 Dec 20. pii: S0022-5347(16)31722-0. doi: 10.1016/j.juro.2016.
    PubMed     Text format    


  103. FU AZ, Tsai HT, Haque R, Ulcickas Yood M, et al
    Mortality and Androgen-Deprivation Therapy as Salvage Treatment for Biochemical Recurrence after Primary Therapy for Clinically Localized Prostate Cancer.
    J Urol. 2016 Dec 19. pii: S0022-5347(16)32071-7. doi: 10.1016/j.juro.2016.
    PubMed     Text format     Abstract available


  104. MEUNIER M, Eyraud R, Senechal C, Gourtaud G, et al
    Active Surveillance for Favorable-Risk Prostate Cancer in African Caribbean Men: Results of a Prospective Study.
    J Urol. 2016 Dec 16. pii: S0022-5347(16)31984-X. doi: 10.1016/j.juro.2016.
    PubMed     Text format     Abstract available


  105. TSAI HT, Pfeiffer RM, Philips GK, Barac A, et al
    Risks of Serious Toxicities from Intermittent versus Continuous Androgen Deprivation Therapy for Advanced Prostate Cancer Patients: A Population-based Study.
    J Urol. 2016 Dec 16. pii: S0022-5347(16)31954-1. doi: 10.1016/j.juro.2016.
    PubMed     Text format     Abstract available


  106. OZGUR BC, Yuceturk CN
    Re: Serum Vitamin D is Not Helpful for Predicting Prostate Cancer Aggressiveness Compared with the Prostate Health Index: C. Stephan, M. Lein, J. Matalon, E. Kilic, Z. Zhao, J. Busch and K. Jung J Urol 2016;196:709-714.
    J Urol. 2016 Dec 16. pii: S0022-5347(16)31584-1. doi: 10.1016/j.juro.2016.
    PubMed     Text format    


  107. ATALA A
    Re: Mesenchymal Stem Cells are Recruited and Activated into Carcinoma-Associated Fibroblasts by Prostate Cancer Microenvironment-Derived TGF-beta1.
    J Urol. 2016;196:1817.
    PubMed     Text format    


  108. SEFTEL AD
    Re: Variation in Testosterone Levels and Health-Related Quality of Life in Men Diagnosed with Prostate Cancer on Active Surveillance.
    J Urol. 2016;196:1723-1724.
    PubMed     Text format    


  109. TANEJA SS
    Re: Lethal Prostate Cancer in the PLCO Cancer Screening Trial.
    J Urol. 2016;196:1677.
    PubMed     Text format    


  110. TANEJA SS
    Re: Use, Complications, and Costs of Stereotactic Body Radiotherapy for Localized Prostate Cancer.
    J Urol. 2016;196:1676-1677.
    PubMed     Text format    


    November 2016
  111. HURLEY P, Dhir A, Gao Y, Drabik B, et al
    A State-wide Intervention Improves Appropriate Imaging in Localized Prostate Cancer.
    J Urol. 2016 Nov 23. pii: S0022-5347(16)31860-2. doi: 10.1016/j.juro.2016.
    PubMed     Text format     Abstract available


  112. MOORE CM, Robertson NL, Jichi F, Damola A, et al
    The effect of dutasteride on MRI-defined prostate cancer lesions: MAPPED (Magnetic resonance imaging in Primary Prostate Cancer after Exposure to Dutasteride) - a randomized placebo-controlled, double-blind clinical trial.
    J Urol. 2016 Nov 18. pii: S0022-5347(16)31794-3. doi: 10.1016/j.juro.2016.
    PubMed     Text format     Abstract available


  113. HAM WS, Chalfin HJ, Feng Z, Trock BJ, et al
    The impact of downgrading from biopsy Gleason 7 to prostatectomy Gleason 6 on biochemical recurrence and prostate cancer-specific mortality.
    J Urol. 2016 Nov 12. pii: S0022-5347(16)31779-7. doi: 10.1016/j.juro.2016.
    PubMed     Text format     Abstract available


  114. LEWICKI P, Shoag J, Golombos DM, Oromendia C, et al
    Prognostic significance of a negative prostate biopsy: An analysis of subjects enrolled in a prostate cancer screening trial.
    J Urol. 2016 Nov 8. pii: S0022-5347(16)31686-X. doi: 10.1016/j.juro.2016.
    PubMed     Text format     Abstract available


  115. ATALA A
    Re: N-Myc Drives Neuroendocrine Prostate Cancer Initiated from Human Prostate Epithelial Cells.
    J Urol. 2016;196:1584-1585.
    PubMed     Text format    


  116. GRIEBLING TL
    Re: Investigation on Lower Urinary Tract Symptoms (LUTS) in Elderly Patients with Prostate Cancer (PC) Received Endocrine Therapy.
    J Urol. 2016;196:1508.
    PubMed     Text format    


  117. KAPLAN SA
    Re: 5alpha-Reductase Inhibitors and the Risk of Cancer-Related Mortality in Men with Prostate Cancer.
    J Urol. 2016;196:1506.
    PubMed     Text format    


  118. SIEGEL C
    Re: Identification of Bone Metastasis with Routine Prostate MRI: A Study of Patients with Newly Diagnosed Prostate Cancer.
    J Urol. 2016;196:1448.
    PubMed     Text format    


  119. SIEGEL C
    Re: Molecular Imaging of Prostate Cancer.
    J Urol. 2016;196:1447-1448.
    PubMed     Text format    


  120. TANEJA SS
    Re: Redirecting Abiraterone Metabolism to Fine-Tune Prostate Cancer Anti-Androgen Therapy.
    J Urol. 2016;196:1447.
    PubMed     Text format    


  121. TANEJA SS
    Re: Hypofractionated Radiotherapy versus Conventionally Fractionated Radiotherapy for Patients with Intermediate-Risk Localised Prostate Cancer: 2-Year Patient-Reported Outcomes of the Randomised, Non-Inferiority, Phase 3 CHHiP Trial.
    J Urol. 2016;196:1445-1447.
    PubMed     Text format    


    October 2016
  122. KIM EH, Andriole GL, Crawford ED, Sjoberg DD, et al
    Detection of High-Grade Prostate Cancer among PLCO Participants Using a Prespecified Four Kallikrein Marker Panel.
    J Urol. 2016 Oct 31. pii: S0022-5347(16)31633-0. doi: 10.1016/j.juro.2016.
    PubMed     Text format     Abstract available


  123. MACLEOD LC, Ellis WJ, Newcomb LF, Zheng Y, et al
    Timing of Adverse Prostate Cancer Reclassification on First Surveillance Biopsy: Results from the Canary Prostate Cancer Active Surveillance Study.
    J Urol. 2016 Oct 31. pii: S0022-5347(16)31634-2. doi: 10.1016/j.juro.2016.
    PubMed     Text format     Abstract available


  124. EIFLER JB, Alvarez J, Koyama T, Conwill RM, et al
    More judicious use of expectant management for localized prostate cancer over the past two decades.
    J Urol. 2016 Oct 27. pii: S0022-5347(16)31611-1. doi: 10.1016/j.juro.2016.
    PubMed     Text format     Abstract available


  125. MAYER MJ, Klotz LH, Venkateswaran V
    The effect of metformin use during docetaxel chemotherapy on prostate cancer-specific and overall survival of diabetic castration-resistant prostate cancer patients.
    J Urol. 2016 Oct 27. pii: S0022-5347(16)31613-5. doi: 10.1016/j.juro.2016.
    PubMed     Text format     Abstract available


  126. BACH-GANSMO T, Nanni C, Nieh PT, Zanoni L, et al
    Multi-site experience of the safety, detection rate and diagnostic performance of fluciclovine (18F) PET/CT imaging in the staging of biochemically recurrent prostate cancer.
    J Urol. 2016 Oct 13. pii: S0022-5347(16)31518-X. doi: 10.1016/j.juro.2016.
    PubMed     Text format     Abstract available


  127. DALL'ERA M, Evans C
    Genomic and Biological Markers to Select Treatment in Patients with Prostate Cancer: Choose Wisely, My Friend.
    J Urol. 2016 Oct 13. pii: S0022-5347(16)31511-7. doi: 10.1016/j.juro.2016.
    PubMed     Text format    


  128. SEFTEL AD
    Re: Recovery of Baseline Erectile Function in Men following Radical Prostatectomy for High-Risk Prostate Cancer: A Prospective Analysis Using Validated Measures.
    J Urol. 2016;196:1228-30.
    PubMed     Text format    


  129. GRIEBLING TL
    Re: Metabolic Syndrome Components are Associated with Increased Prostate Cancer Risk.
    J Urol. 2016;196:1125-6.
    PubMed     Text format    


  130. TANEJA SS
    Re: Addition of Docetaxel, Zoledronic Acid, or Both to First-Line Long-Term Hormone Therapy in Prostate Cancer (STAMPEDE): Survival Results from an Adaptive, Multiarm, Multistage, Platform Randomised Controlled Trial.
    J Urol. 2016;196:1124-5.
    PubMed     Text format    


  131. TANEJA SS
    Re: Association of AR-V7 on Circulating Tumor Cells as a Treatment-Specific Biomarker with Outcomes and Survival in Castration-Resistant Prostate Cancer.
    J Urol. 2016;196:1124.
    PubMed     Text format    


    September 2016
  132. VALERIO M, Dickinson L, Ali A, Ramachadran N, et al
    Nanoknife Electroporation Ablation Trial (NEAT): a prospective development study investigating focal irreversible electroporation for localised prostate cancer.
    J Urol. 2016 Sep 30. pii: S0022-5347(16)31410-0. doi: 10.1016/j.juro.2016.
    PubMed     Text format     Abstract available


  133. ZAFFUTO E, Gandaglia G, Fossati N, Dell'Oglio P, et al
    Early Post-Operative Radiotherapy is Associated with Worse Functional Outcomes in Prostate Cancer Patients.
    J Urol. 2016 Sep 23. pii: S0022-5347(16)31377-5. doi: 10.1016/j.juro.2016.
    PubMed     Text format     Abstract available


  134. NASSIRI N, Margolis DJ, Natarajan S, Sharma DS, et al
    Targeted biopsy to detect Gleason score upgrading during active surveillance for men with low- vs. intermediate-risk prostate cancer.
    J Urol. 2016 Sep 14. pii: S0022-5347(16)31301-5. doi: 10.1016/j.juro.2016.
    PubMed     Text format     Abstract available


  135. KOCH MO
    High Intensity Focused Ultrasound is a Good Treatment Option for Localized Prostate Cancer.
    J Urol. 2016 Sep 13. pii: S0022-5347(16)31235-6. doi: 10.1016/j.juro.2016.
    PubMed     Text format    


  136. AVULOVA S, Moses KA
    High Intensity Focused Ultrasound is a Good Treatment Option for Localized Prostate Cancer.
    J Urol. 2016 Sep 13. pii: S0022-5347(16)31236-8. doi: 10.1016/j.juro.2016.
    PubMed     Text format    


  137. ANTONARAKIS ES, Luo J
    Blood Based Detection of Androgen Receptor Splice Variants in Patients with Advanced Prostate Cancer.
    J Urol. 2016 Sep 9. pii: S0022-5347(16)31226-5. doi: 10.1016/j.juro.2016.
    PubMed     Text format    


  138. FRYE TP, George AK, Kilchevsky A, Maruf M, et al
    MRI-TRUS Guided Fusion Biopsy to Detect Progression in Patients with Existing Lesions on Active Surveillance for Low and Intermediate Risk Prostate Cancer.
    J Urol. 2016 Sep 6. pii: S0022-5347(16)31209-5. doi: 10.1016/j.juro.2016.
    PubMed     Text format     Abstract available


  139. KRISHNA S, Fan Y, Jarosek S, Adejoro O, et al
    Racial disparities in active surveillance for prostate cancer.
    J Urol. 2016 Sep 2. pii: S0022-5347(16)31204-6. doi: 10.1016/j.juro.2016.
    PubMed     Text format     Abstract available


  140. ATALA A
    Re: Bone Metastasis in Prostate Cancer: Recurring Mitochondrial DNA Mutation Reveals Selective Pressure Exerted by the Bone Microenvironment.
    J Urol. 2016;196:957-8.
    PubMed     Text format    


  141. SEFTEL AD
    Re: Endogenous and Exogenous Testosterone and the Risk of Prostate Cancer and Increased Prostate Specific Antigen (PSA): A Meta-Analysis.
    J Urol. 2016;196:856-8.
    PubMed     Text format    


  142. TANEJA SS
    Re: Expectant Management of Veterans with Early-Stage Prostate Cancer.
    J Urol. 2016;196:743-4.
    PubMed     Text format    


  143. TANEJA SS
    Re: Meta-Analysis Evaluating the Impact of Site of Metastasis on Overall Survival in Men with Castration-Resistant Prostate Cancer.
    J Urol. 2016;196:742.
    PubMed     Text format    


  144. TANEJA SS
    Re: Racial Differences in the Surgical Care of Medicare Beneficiaries with Localized Prostate Cancer.
    J Urol. 2016;196:742-3.
    PubMed     Text format    


  145. TANEJA SS
    Re: Enzalutamide versus Bicalutamide in Castration-Resistant Prostate Cancer: The STRIVE Trial.
    J Urol. 2016;196:741-4.
    PubMed     Text format    


  146. CHEN R, Sjoberg DD, Huang Y, Xie L, et al
    Prostate-specific antigen and prostate cancer in Chinese men undergoing initial prostate biopsies in comparison with Western cohorts: data from the PBCG and CPCC.
    J Urol. 2016 Sep 1. pii: S0022-5347(16)31200-9. doi: 10.1016/j.juro.2016.
    PubMed     Text format     Abstract available


  147. CHANG P, Regan MM, Ferrer M, Guedea F, et al
    Relief of Urinary Symptom Burden after Primary Prostate Cancer Treatment.
    J Urol. 2016 Sep 1. pii: S0022-5347(16)31198-3. doi: 10.1016/j.juro.2016.
    PubMed     Text format     Abstract available


    August 2016
  148. DASKIVICH TJ, Wood L, Skarecky D, Ahlering T, et al
    Limitations of the National Comprehensive Cancer Network Guidelines For Prediction of Limited Life Expectancy in Men with Prostate Cancer.
    J Urol. 2016 Aug 28. pii: S0022-5347(16)31192-2. doi: 10.1016/j.juro.2016.
    PubMed     Text format     Abstract available


  149. MAURICE MJ, Sundi D, Schaeffer EM, Abouassaly R, et al
    Risk of Pathological Upgrading and Upstaging among Men with Low-Risk Prostate Cancer Varies By Race: Results from the National Cancer Data Base.
    J Urol. 2016 Aug 28. pii: S0022-5347(16)31184-3. doi: 10.1016/j.juro.2016.
    PubMed     Text format     Abstract available


  150. MUTHIGI A, George AK, Sidana A, Kongnyuy M, et al
    Missing the Mark: Prostate Cancer Upgrading By Systematic Biopsy over MRI/TRUS Fusion Biopsy.
    J Urol. 2016 Aug 28. pii: S0022-5347(16)31193-4. doi: 10.1016/j.juro.2016.
    PubMed     Text format     Abstract available


  151. MUSUNURU HB, Yamamoto T, Klotz L, Ghanem G, et al
    Active Surveillance for Intermediate Risk Prostate Cancer: Survival Outcomes in the Sunnybrook Experience.
    J Urol. 2016 Aug 26. pii: S0022-5347(16)31142-9. doi: 10.1016/j.juro.2016.
    PubMed     Text format     Abstract available


  152. KLEIN EA, Santiago-Jimenez M, Yousefi K, Robbins BA, et al
    Molecular analysis of low grade prostate cancer utilizing a genomic classifier of metastatic potential.
    J Urol. 2016 Aug 25. pii: S0022-5347(16)31146-6. doi: 10.1016/j.juro.2016.
    PubMed     Text format     Abstract available


  153. ZHAO F, Olkhov-Mitsel E, van der Kwast T, Sykes J, et al
    Urinary DNA methylation biomarkers for non-invasive prediction of aggressive disease in prostate cancer patients on Active Surveillance.
    J Urol. 2016 Aug 18. pii: S0022-5347(16)31067-9. doi: 10.1016/j.juro.2016.
    PubMed     Text format     Abstract available


  154. RAMSAY E, Mougenot C, Staruch R, Boyes A, et al
    Evaluation of focal ablation of MRI-defined prostate cancer using MRI-controlled transurethral ultrasound therapy with prostatectomy as the reference standard.
    J Urol. 2016 Aug 18. pii: S0022-5347(16)31072-2. doi: 10.1016/j.juro.2016.
    PubMed     Text format    


  155. HARRIS CR, McAninch JW, Mundy AR, Zinman LN, et al
    Rectourethral Fistulas Secondary to Prostate Cancer Treatment: Management and Outcomes from a Multi-Institutional Combined Experience.
    J Urol. 2016 Aug 17. pii: S0022-5347(16)31066-7. doi: 10.1016/j.juro.2016.
    PubMed     Text format     Abstract available


  156. GLEAVE ME, Klotz L
    Testosterone Therapy Can be Given to Men with No Concern that it will Promote Prostate Cancer Development or Progression: Con.
    J Urol. 2016 Aug 9. pii: S0022-5347(16)30988-0. doi: 10.1016/j.juro.2016.
    PubMed     Text format    


  157. OROM H, Underwood W 3rd, Biddle C
    Emotional distress increases the likelihood of receiving surgery among men with localized prostate cancer.
    J Urol. 2016 Aug 6. pii: S0022-5347(16)30973-9. doi: 10.1016/j.juro.2016.
    PubMed     Text format     Abstract available


  158. ATALA A
    Re: Dietary Flavonoid Fisetin Binds to beta-Tubulin and Disrupts Microtubule Dynamics in Prostate Cancer Cells.
    J Urol. 2016;196:618.
    PubMed     Text format    


  159. WEIN AJ
    Re: A Review of Detrusor Overactivity and the Overactive Bladder after Radical Prostate Cancer Treatment.
    J Urol. 2016;196:500-1.
    PubMed     Text format    


  160. SIEGEL C
    Re: Molecular Imaging of Prostate Cancer.
    J Urol. 2016;196:415.
    PubMed     Text format    


  161. TANEJA SS
    Re: Focal Ablation Targeted to the Index Lesion in Multifocal Localised Prostate Cancer: A Prospective Development Study.
    J Urol. 2016;196:414.
    PubMed     Text format    


  162. TANEJA SS
    Re: Adverse Health Events following Intermittent and Continuous Androgen Deprivation in Patients with Metastatic Prostate Cancer.
    J Urol. 2016;196:412-4.
    PubMed     Text format    


  163. TANEJA SS
    Re: Risk Group and Death from Prostate Cancer: Implications for Active Surveillance in Men with Favorable Intermediate-Risk Prostate Cancer.
    J Urol. 2016;196:412-3.
    PubMed     Text format    


    July 2016
  164. PRIESTER A, Natarajan S, Khoshnoodi P, Margolis DJ, et al
    MRI Underestimation of Prostate Cancer Geometry: Use of Patient-Specific Molds to Correlate Images with Whole-Mount Pathology.
    J Urol. 2016 Jul 30. pii: S0022-5347(16)30958-2. doi: 10.1016/j.juro.2016.
    PubMed     Text format     Abstract available


  165. YAN W
    Re: More Favorable Pathological Outcomes in Men with Low Risk Prostate Cancer Diagnosed on Repeat versus Initial Transrectal Ultrasound Guided Prostate Biopsy: A. ElShafei, Y. Nyame, O. Kara, A. Badawy, I. Amujiogu, K. Fareed, E. Klein and J. S. Jones
    J Urol. 2016 Jul 29. pii: S0022-5347(16)30584-5. doi: 10.1016/j.juro.2016.
    PubMed     Text format    


  166. WAGNER AA, Cheng PJ, Carneiro A, Dovirak O, et al
    Clinical Use of EPIC for Clinical Practice (EPIC-CP) to Assess Patient-Reported Prostate Cancer Quality-of-Life Following Robot-Assisted Radical Prostatectomy.
    J Urol. 2016 Jul 27. pii: S0022-5347(16)30925-9. doi: 10.1016/j.juro.2016.
    PubMed     Text format     Abstract available


  167. PERLIS N, Sayyid R, Evans A, Van Der Kwast T, et al
    Limitations in predicting organ-confined prostate cancer in patients with Gleason pattern 4 on biopsy: Implications for active surveillance.
    J Urol. 2016 Jul 22. pii: S0022-5347(16)30919-3. doi: 10.1016/j.juro.2016.
    PubMed     Text format     Abstract available


  168. EGEVAD L, Samaratunga H, Srigley JR, Delahunt B, et al
    Re: Consensus Guidelines for Reporting Prostate Cancer Gleason Grade: A Zietman, E. Klein, M. J. Droller, P. Dasgupta, J. Catto and J. A. Smith, Jr. J Urol 2016;195: 1723.
    J Urol. 2016 Jul 20. pii: S0022-5347(16)30858-8. doi: 10.1016/j.juro.2016.
    PubMed     Text format    


  169. EGGENER SE, Yousuf A, Watson S, Wang S, et al
    Phase II Evaluation of MRI-Guided Focal Laser Ablation of Prostate Cancer.
    J Urol. 2016 Jul 20. pii: S0022-5347(16)30917-X. doi: 10.1016/j.juro.2016.
    PubMed     Text format     Abstract available


  170. SOBOL I, Zaid HB, Haloi R, Mynderse LA, et al
    Contemporary Mapping of Post-Prostatectomy Prostate Cancer Relapse with C-11 Choline PET and Multiparametric MRI.
    J Urol. 2016 Jul 20. pii: S0022-5347(16)30916-8. doi: 10.1016/j.juro.2016.
    PubMed     Text format     Abstract available


  171. GLEAVE ME, Klotz L
    Testosterone Therapy Can be Given to Men with No Concern that it will Promote Prostate Cancer Development or Progression.
    J Urol. 2016 Jul 20. pii: S0022-5347(16)30918-1. doi: 10.1016/j.juro.2016.
    PubMed     Text format    


  172. LIU X, Ledet E, Li D, Dotiwala A, et al
    A Whole Blood Assay for AR-V7 and ARv567es in Prostate Cancer Patients.
    J Urol. 2016 Jul 20. pii: S0022-5347(16)30914-4. doi: 10.1016/j.juro.2016.
    PubMed     Text format     Abstract available


  173. TODENHOFER T, Azad A, Stewart C, Gao J, et al
    AR-V7 transcripts in whole blood RNA of patients with metastatic castration resistant prostate cancer correlate with response to Abiraterone acetate.
    J Urol. 2016 Jul 16. pii: S0022-5347(16)30860-6. doi: 10.1016/j.juro.2016.
    PubMed     Text format     Abstract available


  174. HERREL LA, Kaufman SR, Yan P, Miller DC, et al
    Healthcare integration and quality among men with prostate cancer.
    J Urol. 2016 Jul 13. pii: S0022-5347(16)30826-6. doi: 10.1016/j.juro.2016.
    PubMed     Text format     Abstract available


  175. CHER ML, Dhir A, Auffenberg GB, Linsell S, et al
    Appropriateness Criteria for Active Surveillance of Prostate Cancer.
    J Urol. 2016 Jul 12. pii: S0022-5347(16)30778-9. doi: 10.1016/j.juro.2016.
    PubMed     Text format     Abstract available


  176. GRIEBLING TL
    Re: Clinical Outcomes of Helical Tomotherapy for Super-Elderly Patients with Localized and Locally Advanced Prostate Cancer: Comparison with Patients under 80 Years of Age.
    J Urol. 2016;196:107.
    PubMed     Text format    


  177. GRIEBLING TL
    Re: Treatment Patterns for Older Veterans with Localized Prostate Cancer.
    J Urol. 2016;196:107-8.
    PubMed     Text format    


  178. PENSON DF
    Re: Annual Medical Expenditure and Productivity Loss among Colorectal, Female Breast, and Prostate Cancer Survivors in the United States.
    J Urol. 2016;196:105.
    PubMed     Text format    


  179. PENSON DF
    Re: Prostate Cancer Incidence and PSA Testing Patterns in Relation to USPSTF Screening Recommendations.
    J Urol. 2016;196:105-6.
    PubMed     Text format    


  180. TANEJA SS
    Re: Prostate-Specific Antigen Decline after 4 Weeks of Treatment with Abiraterone Acetate and Overall Survival in Patients with Metastatic Castration-Resistant Prostate Cancer.
    J Urol. 2016;196:103.
    PubMed     Text format    


  181. TANEJA SS
    Re: Medium-Term Outcomes after Whole-Gland High-Intensity Focused Ultrasound for the Treatment of Nonmetastatic Prostate Cancer from a Multicentre Registry Cohort.
    J Urol. 2016;196:103-4.
    PubMed     Text format    


  182. TANEJA SS
    Re: Prostate Cancer Detection with Magnetic Resonance-Ultrasound Fusion Biopsy: The Role of Systematic and Targeted Biopsies.
    J Urol. 2016;196:101-2.
    PubMed     Text format    


    June 2016
  183. LEAPMAN MS, Freedland SJ, Aronson WJ, Kane CJ, et al
    Pathologic and Biochemical Outcomes among African-American and Caucasian Men with Low-Risk Prostate Cancer in the SEARCH Database: Implications for Active Surveillance Candidacy.
    J Urol. 2016 Jun 25. pii: S0022-5347(16)30747-9. doi: 10.1016/j.juro.2016.
    PubMed     Text format     Abstract available


  184. KOMISARENKO M, Timilshina N, Richard PO, Alibhai SM, et al
    Stricter active surveillance criteria for prostate cancer do not result in significantly better outcomes: A comparison of contemporary protocols.
    J Urol. 2016 Jun 24. pii: S0022-5347(16)30744-3. doi: 10.1016/j.juro.2016.
    PubMed     Text format     Abstract available


  185. JOHNSON DC, Mueller DE, Deal AM, Dunn MW, et al
    Integrating patient preferences into treatment decisions for men with prostate cancer at the point of care.
    J Urol. 2016 Jun 23. pii: S0022-5347(16)30743-1. doi: 10.1016/j.juro.2016.
    PubMed     Text format     Abstract available


  186. KRYVENKO ON, Epstein JI, Cote RJ
    Do Black Non-Hispanic Men Produce Less Prostate Specific Antigen in Benign Prostate Tissue or Cancer Compared to White Non-Hispanic Men with Gleason Score 6 (Grade Group 1) Prostate Cancer?
    J Urol. 2016 Jun 22. pii: S0022-5347(16)30740-6. doi: 10.1016/j.juro.2016.
    PubMed     Text format     Abstract available


  187. THORSTENSON A, Garmo H, Adolfsson J, Bratt O, et al
    Cancer-specific mortality in men diagnosed with prostate cancer before age 50 years, a nationwide population-based study.
    J Urol. 2016 Jun 17. pii: S0022-5347(16)30660-7. doi: 10.1016/j.juro.2016.
    PubMed     Text format     Abstract available


  188. ROSENKRANTZ AB, Verma S, Choyke P, Eberhardt SC, et al
    Prostate MRI and MRI-Targeted Biopsy in Patients with a Prior Negative Biopsy: A Consensus Statement of the American Urological Association and the Society of Abdominal Radiology's Prostate Cancer Disease-Focused Panel.
    J Urol. 2016 Jun 16. pii: S0022-5347(16)30659-0. doi: 10.1016/j.juro.2016.
    PubMed     Text format     Abstract available


  189. DALL'ERA MA
    Reasons for Abandonment of Active Surveillance in Men with Prostate Cancer.
    J Urol. 2016 Jun 14. pii: S0022-5347(16)30658-9. doi: 10.1016/j.juro.2016.
    PubMed     Text format    


  190. BAUMANN BC, Guzzo TJ, Christodouleas JP
    Re: Anatomical Patterns of Recurrence following Biochemical Relapse in the Dose Escalation Era of External Beam Radiotherapy for Prostate Cancer: Z. S. Zumsteg, D. E. Spratt, P. B. Romesser, X. Pei, Z. Zhang, M. Kollmeier, S. McBride, Y. Yamada and M.
    J Urol. 2016 Jun 10. pii: S0022-5347(16)30281-6. doi: 10.1016/j.juro.2016.
    PubMed     Text format    


  191. KRYVENKO ON, Epstein JI
    Definition of Insignificant Tumor Volume of Gleason Score 3+3=6 (Grade Group 1) Prostate Cancer at Radical Prostatectomy - Is it Time to Increase the Threshold?
    J Urol. 2016 Jun 9. pii: S0022-5347(16)30586-9. doi: 10.1016/j.juro.2016.
    PubMed     Text format     Abstract available


  192. TANEJA SS, Bennett J, Coleman J, Grubb R, et al
    Final Results of a Phase I/II Multicenter Trial of WST11 (TOOKAD(R) Soluble) Vascular-Targeted Photodynamic Therapy (VTP) for Hemiablation of the Prostate in Men with Unilateral Low Risk Prostate Cancer Conducted in the United States.
    J Urol. 2016 Jun 9. pii: S0022-5347(16)30587-0. doi: 10.1016/j.juro.2016.
    PubMed     Text format     Abstract available


  193. HARDING-JACKSON N, Kryvenko ON, Whittington EE, Eastwood DC, et al
    Outcome of Gleason 3+5=8 Prostate Cancer Diagnosed on Needle Biopsy: Prognostic Comparison with Gleason 4+4=8.
    J Urol. 2016 Jun 2. pii: S0022-5347(16)30556-0. doi: 10.1016/j.juro.2016.
    PubMed     Text format     Abstract available


  194. ATALA A
    Re: Autophagy Defects Suggested by Low Levels of Autophagy Activator MAP1S and High Levels of Autophagy Inhibitor LRPPRC Predict Poor Prognosis of Prostate Cancer Patients.
    J Urol. 2016;195:1948-9.
    PubMed     Text format    


  195. CADEDDU JA
    Re: Complications, Recovery, and Early Functional Outcomes and Oncologic Control following In-Bore Focal Laser Ablation of Prostate Cancer.
    J Urol. 2016;195:1782-3.
    PubMed     Text format    


  196. SIEGEL C
    Re: Benign Conditions that Mimic Prostate Carcinoma: MR Imaging Features with Histopathologic Correlation.
    J Urol. 2016;195:1782.
    PubMed     Text format    


  197. TANEJA SS
    Re: Nine-Year Follow-up for a Study of Diffusion-Weighted Magnetic Resonance Imaging in a Prospective Prostate Cancer Active Surveillance Cohort.
    J Urol. 2016;195:1781-2.
    PubMed     Text format    


  198. TANEJA SS
    Re: Statin Use at the Time of Initiation of Androgen Deprivation Therapy and Time to Progression in Patients with Hormone-Sensitive Prostate Cancer.
    J Urol. 2016;195:1780-1.
    PubMed     Text format    


  199. TANEJA SS
    Re: Validation of an RNA Cell Cycle Progression Score for Predicting Death from Prostate Cancer in a Conservatively Managed Needle Biopsy Cohort.
    J Urol. 2016;195:1779-80.
    PubMed     Text format    


    May 2016
  200. VICTORSON DE, Schuette S, Schalet BD, Kundu SD, et al
    Factors Affecting Quality of Life at Different Time Points since Treatment in a Sample of Men with Localized Prostate Cancer: The Unique Influence of Treatment Decision Making Satisfaction, Personality, and Sexual Functioning.
    J Urol. 2016 May 31. pii: S0022-5347(16)30548-1. doi: 10.1016/j.juro.2016.
    PubMed     Text format     Abstract available


  201. AUFFENBERG GB, Linsell S, Dhir A, Myers SN, et al
    Comparison of pathologic outcomes for men with low-risk prostate cancer from diverse practice settings-similar results from immediate prostatectomy or initial surveillance with delayed prostatectomy.
    J Urol. 2016 May 30. pii: S0022-5347(16)30544-4. doi: 10.1016/j.juro.2016.
    PubMed     Text format     Abstract available


  202. JOHNSON MH, Ross AE, Alshalalfa M, Erho N, et al
    SPINK1 defines a molecular subtype of prostate cancer in men with more rapid progression in an at-risk, natural history radical prostatectomy cohort.
    J Urol. 2016 May 26. pii: S0022-5347(16)30533-X. doi: 10.1016/j.juro.2016.
    PubMed     Text format     Abstract available


  203. RAMIREZ-BACKHAUS M, Mira Moreno A, Gomez Ferrer A, Calatrava Fons A, et al
    Indocyanine Green guided pelvic lymph node dissection. An efficient technique to classify the lymph node status of patients with prostate cancer who underwent radical prostatectomy.
    J Urol. 2016 May 25. pii: S0022-5347(16)30511-0. doi: 10.1016/j.juro.2016.
    PubMed     Text format     Abstract available


  204. RHEE H, Thomas P, Shepherd B, Greenslade S, et al
    PSMA PET May Improve the Diagnostic Accuracy of mpMRI in Localised Prostate Cancer as Confirmed by Whole-Mount Histopathology.
    J Urol. 2016 May 21. pii: S0022-5347(16)30505.
    PubMed     Text format     Abstract available


  205. POYET C, Wettstein MS, Lundon DJ, Bhindi B, et al
    External evaluation of a novel prostate cancer risk calculator (ProstateCheck) based on data of the Swiss arm of the ERSPC.
    J Urol. 2016 May 14. pii: S0022-5347(16)30453-0. doi: 10.1016/j.juro.2016.
    PubMed     Text format     Abstract available


  206. ROACH M 3RD
    Surgery Provides Better Oncologic Outcomes than Radiation for the Treatment of Prostate Cancer.
    J Urol. 2016 May 6. pii: S0022-5347(16)30358-5. doi: 10.1016/j.juro.2016.
    PubMed     Text format    


  207. KLOTZ L, Evans CP
    Surgery Provides Better Oncologic Outcomes than Radiation for the Treatment of Prostate Cancer: Pro.
    J Urol. 2016 May 6. pii: S0022-5347(16)30359-7. doi: 10.1016/j.juro.2016.
    PubMed     Text format    


  208. AL-TARTIR T, Murekeyisoni C, Attwood K, Badkhshan S, et al
    Outcomes of Scheduled Versus For-Cause Biopsy Regimens for Prostate Cancer Active Surveillance.
    J Urol. 2016 May 5. pii: S0022-5347(16)30349-4. doi: 10.1016/j.juro.2016.
    PubMed     Text format     Abstract available


  209. SIDDIQUI KM, Billia M, Al-Zahrani A, Williams A, et al
    Long-Term Oncological Outcomes of Salvage Cryoablation for Radio-Recurrent Prostate Cancer.
    J Urol. 2016 May 5. pii: S0022-5347(16)30337-8. doi: 10.1016/j.juro.2016.
    PubMed     Text format     Abstract available


  210. AGARWAL N, Alex AB, Farnham JM, Patel S, et al
    Inherited variants in SULT1E1 and response to abiraterone acetate in men with metastatic castration refractory prostate cancer (mCRPC).
    J Urol. 2016 May 2. pii: S0022-5347(16)30328-7. doi: 10.1016/j.juro.2016.
    PubMed     Text format     Abstract available


  211. PENSON DF
    Re: Trends in Prostate-Specific Antigen Screening, Prostate Biopsies, Urology Visits, and Prostate Cancer Treatments from 2000 to 2012.
    J Urol. 2016;195:1473-4.
    PubMed     Text format    


  212. TANEJA SS
    Re: Androgen Receptor Splice Variant 7 and Efficacy of Taxane Chemotherapy in Patients with Metastatic Castration-Resistant Prostate Cancer.
    J Urol. 2016;195:1472-3.
    PubMed     Text format    


  213. TANEJA SS
    Re: Long-Term Follow-up of a Randomized Trial of Radiation with or without Androgen Deprivation Therapy for Localized Prostate Cancer.
    J Urol. 2016;195:1471-3.
    PubMed     Text format    


  214. LABOSSIERE JR, Cheung D, Rourke K
    Endoscopic Treatment of Vesicourethral Stenosis after Radical Prostatectomy: Outcomes and Predictors of Success.
    J Urol. 2016;195:1495-500.
    PubMed     Text format     Abstract available


    April 2016
  215. ORY J, Flannigan R, Lundeen C, Huang JG, et al
    Testosterone Therapy In Patients With Treated and Untreated Prostate Cancer: Impact on Oncologic Outcomes.
    J Urol. 2016 Apr 27. pii: S0022-5347(16)30307-X. doi: 10.1016/j.juro.2016.
    PubMed     Text format     Abstract available


  216. ELTEMAMY MM, Leapman MS, Cowan JE, Westphalen A, et al
    Serial Anatomic Prostate Ultrasound Imaging During Prostate Cancer Active Surveillance.
    J Urol. 2016 Apr 23. pii: S0022-5347(16)30287-7. doi: 10.1016/j.juro.2016.
    PubMed     Text format     Abstract available


  217. MURRAY KS, Ehdaie B, Musser J, Mashni J, et al
    Pilot Study to Assess Safety and Clinical Outcomes of Irreversible Electroporation for Partial Gland Ablation in Men with Prostate Cancer.
    J Urol. 2016 Apr 22. pii: S0022-5347(16)30278.
    PubMed     Text format     Abstract available


  218. MERTAN FV, Greer MD, Shih JH, George AK, et al
    Prospective Evaluation of the Prostate Imaging Reporting and Data System version 2 (PI-RADSv2) for Prostate Cancer Detection.
    J Urol. 2016 Apr 18. pii: S0022-5347(16)30199-9. doi: 10.1016/j.juro.2016.
    PubMed     Text format     Abstract available


  219. KELLY SP, Van Den Eeden SK, Hoffman RM, Aaronson DS, et al
    Sociodemographic and clinical predictors of switching to active treatment among a large ethnically diverse cohort of men with low-risk prostate cancer on observational management.
    J Urol. 2016 Apr 14. pii: S0022-5347(16)30184-7. doi: 10.1016/j.juro.2016.
    PubMed     Text format     Abstract available


  220. DELONGCHAMPS NB, Portalez D, Bruguiere E, Rouviere O, et al
    Are MRI-TRUS-guided targeted biopsies non-inferior to TRUS-guided systematic biopsies for the detection of prostate cancer in patients with a single suspicious focus on multiparametric prostate MRI? Results of a multicentric controlled trial.
    J Urol. 2016 Apr 11. pii: S0022-5347(16)30142-2. doi: 10.1016/j.juro.2016.
    PubMed     Text format     Abstract available


  221. JAMNAGERWALLA J, Howard LE, Vidal AC, Moreira DM, et al
    The Association Between Phosphodiesterase Type-5 Inhibitors and Prostate Cancer: Results from the REDUCE Study.
    J Urol. 2016 Apr 5. pii: S0022-5347(16)30127-6. doi: 10.1016/j.juro.2016.
    PubMed     Text format     Abstract available


  222. SHOAG J, Halpern JA, Lee DJ, Mittal S, et al
    Decline in prostate cancer screening by primary care physicians: an analysis of trends in the use of digital rectal examination and prostate specific antigen testing.
    J Urol. 2016 Apr 5. pii: S0022-5347(16)30126-4. doi: 10.1016/j.juro.2016.
    PubMed     Text format     Abstract available


  223. SIEGEL C
    Re: Detection of Local Recurrence of Prostate Cancer after Radical Prostatectomy Using Endorectal Coil MRI at 3 T: Addition of DWI and Dynamic Contrast Enhancement to T2-Weighted MRI.
    J Urol. 2016;195.
    PubMed     Text format    


  224. PENSON DF
    Re: National Prostate Cancer Screening Rates after the 2012 US Preventive Services Task Force Recommendation Discouraging Prostate-Specific Antigen-Based Screening.
    J Urol. 2016;195.
    PubMed     Text format    


  225. TANEJA SS
    Re: Prostate Cancer Incidence and PSA Testing Patterns in Relation to USPSTF Screening Recommendations.
    J Urol. 2016;195.
    PubMed     Text format    


  226. TANEJA SS
    Re: DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer.
    J Urol. 2016;195.
    PubMed     Text format    


  227. REESINK DJ, Fransen van de Putte EE, Vegt E, De Jong J, et al
    Clinical Relevance of Incidental Prostatic Lesions on FDG-Positron Emission Tomography/Computerized Tomography-Should Patients Receive Further Evaluation?
    J Urol. 2016;195.
    PubMed     Text format     Abstract available


  228. MAURICE MJ, Zhu H, Kiechle JE, Kim SP, et al
    Comorbid Disease Burden is Independently Associated with Higher Risk Disease at Prostatectomy in Patients Eligible for Active Surveillance.
    J Urol. 2016;195.
    PubMed     Text format     Abstract available


    March 2016
  229. VAN DEN BOS W, Jurhill RR, de Bruin DM, Savci-Heijink CD, et al
    Histopathological outcomes after irreversible electroporation in prostate cancer; Results of an ablate-and-resect study.
    J Urol. 2016 Mar 19. pii: S0022-5347(16)03679.
    PubMed     Text format     Abstract available


  230. KIM M, Choi SK, Park M, Shim M, et al
    Characteristics of anteriorly located prostate cancer and the usefulness of multiparametric magnetic resonance imaging for its diagnosis.
    J Urol. 2016 Mar 17. pii: S0022-5347(16)03461-3. doi: 10.1016/j.juro.2016.
    PubMed     Text format     Abstract available


  231. ANKERST DP, Gelfond J, Goros M, Herrera J, et al
    Serial Percent-Free PSA in Combination with PSA for Population-Based Early Detection of Prostate Cancer.
    J Urol. 2016 Mar 12. pii: S0022-5347(16)03383-8. doi: 10.1016/j.juro.2016.
    PubMed     Text format     Abstract available


  232. PHAM KN, Cullen J, Hurwitz LM, Wolff EM, et al
    Prospective Quality of Life in Men Choosing Active Surveillance Compared to Those Biopsied but not Diagnosed with Prostate Cancer.
    J Urol. 2016 Mar 11. pii: S0022-5347(16)03378.
    PubMed     Text format     Abstract available


  233. STEPHAN C, Lein M, Matalon J, Kilic E, et al
    Serum Vitamin D is not Helpful in Predicting Prostate Cancer Aggressiveness Compared with the Prostate Health Index.
    J Urol. 2016 Mar 11. pii: S0022-5347(16)03380-2. doi: 10.1016/j.juro.2016.
    PubMed     Text format     Abstract available


  234. HECK MM, Retz M, D Alessandria C, Rauscher I, et al
    Systemic radioligand therapy with Lu-PSMA-I&T in patients with metastatic castration-resistant prostate cancer.
    J Urol. 2016 Mar 7. pii: S0022-5347(16)03361-9. doi: 10.1016/j.juro.2016.02.2969
    PubMed     Text format     Abstract available


  235. LOEB S, Walter D, Curnyn C, Gold HT, et al
    How Active is Active Surveillance? Intensity of Follow-Up During Active Surveillance for Prostate Cancer in the United States.
    J Urol. 2016 Mar 2. pii: S0022-5347(16)03325-5. doi: 10.1016/j.juro.2016.02.2963
    PubMed     Text format     Abstract available


  236. ATALA A
    Re: Expression of Nuclear Matrix Proteins Binding Matrix Attachment Regions in Prostate Cancer. PARP-1: New Player in Tumor Progression.
    J Urol. 2016;195:801-2.
    PubMed     Text format    


  237. SIEGEL C
    Re: Apparent Diffusion Coefficient Values of the Benign Central Zone of the Prostate: Comparison with Low- and High-Grade Prostate Cancer.
    J Urol. 2016;195:629.
    PubMed     Text format    


  238. TANEJA SS
    Re: Dose-Escalated Irradiation and Overall Survival in Men with Nonmetastatic Prostate Cancer.
    J Urol. 2016;195:628.
    PubMed     Text format    


  239. TANEJA SS
    Re: Difference in Association of Obesity with Prostate Cancer Risk between US African American and Non-Hispanic White Men in the Selenium and Vitamin E Cancer Prevention Trial (SELECT).
    J Urol. 2016;195:627-8.
    PubMed     Text format    


  240. TANEJA SS
    Re: Prostate Biopsy Specimens with Gleason 3+3=6 and Intraductal Carcinoma: Radical Prostatectomy Findings and Clinical Outcomes.
    J Urol. 2016;195:627.
    PubMed     Text format    


  241. BORA GS, Gupta VG, Mavuduru RS
    Re: Use of Phosphodiesterase Type 5 Inhibitors May Adversely Impact Biochemical Recurrence after Radical Prostatectomy: U. Michl, F. Molfenter, M. Graefen, P. Tennstedt, S. Ahyai, B. Beyer, L. Budaus, A. Haese, H. Heinzer, S. J. Oh, G. Salomon, T. Sch
    J Urol. 2016;195:804.
    PubMed     Text format    


  242. SEFTEL AD
    Re: Unexpected Long-Term Improvements in Urinary and Erectile Function in a Large Cohort of Men with Self-Reported Outcomes following Radical Prostatectomy.
    J Urol. 2016;195:713-4.
    PubMed     Text format    


  243. SEFTEL AD
    Re: Erectile Dysfunction in 1050 Men following Extended (18 Cores) vs Saturation (28 Cores) vs Saturation plus MRI-Targeted Prostate Biopsy (32 Cores).
    J Urol. 2016;195:714-5.
    PubMed     Text format    


    February 2016
  244. BOEHM K, Larcher A, Tian Z, Mandel P, et al
    Low other cause mortality rates reflect good patient selection in prostate cancer patients treated with radical prostatectomy.
    J Urol. 2016 Feb 26. pii: S0022-5347(16)03247-X. doi: 10.1016/j.juro.2016.
    PubMed     Text format     Abstract available


  245. RECABAL P, Assel M, Sjoberg DD, Lee D, et al
    The Efficacy of Multiparametric Magnetic Resonance Imaging and MRI-Targeted Biopsy in Risk Classification for Patients with Prostate Cancer on Active Surveillance.
    J Urol. 2016 Feb 23. pii: S0022-5347(16)00372-4. doi: 10.1016/j.juro.2016.
    PubMed     Text format     Abstract available


  246. COOPERBERG M
    When to Start Prostate Cancer Screening and When to Stop: Insights from Goteborg.
    J Urol. 2016 Feb 18. pii: S0022-5347(16)00360-8. doi: 10.1016/j.juro.2016.
    PubMed     Text format    


  247. NAM RK, Wallis CJ, Stojcic-Bendavid J, Milot L, et al
    A Pilot Study to Evaluate the Role of Magnetic Resonance Imaging for Prostate Cancer Screening in the General Population.
    J Urol. 2016 Feb 12. pii: S0022-5347(16)00332-3. doi: 10.1016/j.juro.2016.
    PubMed     Text format     Abstract available


  248. CHELLURI R, Kilchevsky A, George AK, Sidana A, et al
    Prostate Cancer Diagnosis on repeat MRI-TRUS Fusion Biopsy of Benign Lesions: Recommendations for Repeat Sampling.
    J Urol. 2016 Feb 12. pii: S0022-5347(16)00327-X. doi: 10.1016/j.juro.2016.
    PubMed     Text format     Abstract available


  249. TAN HJ, Marks LS, Hoyt MA, Kwan L, et al
    The relationship between intolerance of uncertainty and anxiety in men on active surveillance for prostate cancer.
    J Urol. 2016 Feb 9. pii: S0022-5347(16)00270-6. doi: 10.1016/j.juro.2016.
    PubMed     Text format     Abstract available


  250. ATALA A
    Re: Regulation of the ITGA2 Gene by Epigenetic Mechanisms in Prostate Cancer.
    J Urol. 2016;195:525.
    PubMed     Text format    


  251. ATALA A
    Re: PLCepsilon Knockdown Inhibits Prostate Cancer Cell Proliferation via Suppression of Notch Signalling and Nuclear Translocation of the Androgen Receptor.
    J Urol. 2016;195:524-5.
    PubMed     Text format    


  252. PENSON DF
    Re: Intermittent vs Continuous Androgen Deprivation Therapy for Prostate Cancer: A Systematic Review and Meta-Analysis.
    J Urol. 2016;195:353-4.
    PubMed     Text format    


  253. PENSON DF
    Re: Trends in Management for Patients with Localized Prostate Cancer, 1990-2013.
    J Urol. 2016;195:353-4.
    PubMed     Text format    


  254. SIEGEL C
    Re: Anterior Prostate Cancer: Diagnostic Performance of T2-Weighted MRI and an Apparent Diffusion Coefficient Map.
    J Urol. 2016;195:352.
    PubMed     Text format    


  255. TANEJA SS
    Re: Importance of Local Control in Early-Stage Prostate Cancer: Outcomes of Patients with Positive Post-Radiation Therapy Biopsy Results Treated in RTOG 9408.
    J Urol. 2016;195:351-2.
    PubMed     Text format    


  256. TANEJA SS
    Re: Survival with Newly Diagnosed Metastatic Prostate Cancer in the "Docetaxel Era": Data from 917 Patients in the Control Arm of the STAMPEDE Trial (MRC PR08, CRUK/06/019).
    J Urol. 2016;195:350.
    PubMed     Text format    


  257. TANEJA SS
    Re: National Prostate Cancer Screening Rates after the 2012 US Preventive Services Task Force Recommendation Discouraging Prostate-Specific Antigen-Based Screening.
    J Urol. 2016;195:350-1.
    PubMed     Text format    


  258. SCHAEFFER EM
    Re: Multiparametric MRI Findings of Granulomatous Prostatitis after Intravesical bacillus Calmette-Guerin Therapy in a Patient Undergoing Active Surveillance.
    J Urol. 2016;195:371.
    PubMed     Text format    


  259. GRIEBLING TL
    Re: Early Urinary Continence Recovery after Robot-Assisted Radical Prostatectomy in Older Australian Men.
    J Urol. 2016;195:354-5.
    PubMed     Text format    


  260. CADEDDU JA
    Re: Urinary Incontinence and Erectile Dysfunction after Robotic versus Open Radical Prostatectomy: A Prospective, Controlled, Nonrandomised Trial.
    J Urol. 2016;195:354.
    PubMed     Text format    


  261. TANEJA SS
    Re: Does Preoperative Magnetic Resonance Imaging Reduce the Rate of Positive Surgical Margins at Radical Prostatectomy in a Randomised Clinical Trial?
    J Urol. 2016;195:349.
    PubMed     Text format    


  262. ELLIS WJ
    Should Clinicians Use Ultrasensitive Prostate Specific Antigen Measurements for Patient Evaluation?
    J Urol. 2016;195:243-4.
    PubMed     Text format    


  263. ZLATEV DV, Liao JC
    Editorial Comment.
    J Urol. 2016;195:483-4.
    PubMed     Text format    


  264. KOMISARENKO M, Wong LM, Richard PO, Timilshina N, et al
    An Increase in Gleason 6 Tumor Volume While on Active Surveillance Portends a Greater Risk of Grade Reclassification with Further Followup.
    J Urol. 2016;195:307-12.
    PubMed     Text format     Abstract available


  265. O'NEIL B, Koyama T, Alvarez J, Conwill RM, et al
    The Comparative Harms of Open and Robotic Prostatectomy in Population Based Samples.
    J Urol. 2016;195:321-9.
    PubMed     Text format     Abstract available


  266. SOKOLL LJ, Zhang Z, Chan DW, Reese AC, et al
    Do Ultrasensitive Prostate Specific Antigen Measurements Have a Role in Predicting Long-Term Biochemical Recurrence-Free Survival in Men after Radical Prostatectomy?
    J Urol. 2016;195:330-6.
    PubMed     Text format     Abstract available


  267. KATES M, Sopko NA, Han M, Partin AW, et al
    Importance of Reporting the Gleason Score at the Positive Surgical Margin Site: Analysis of 4,082 Consecutive Radical Prostatectomy Cases.
    J Urol. 2016;195:337-42.
    PubMed     Text format     Abstract available


  268. BRATH JM, Grill S, Ankerst DP, Thompson IM Jr, et al
    No Detrimental Effect of a Positive Family History on Long-Term Outcomes Following Radical Prostatectomy.
    J Urol. 2016;195:343-8.
    PubMed     Text format     Abstract available


    January 2016
  269. SCHADE GR, Holt S, Zhang X, Song D, et al
    Prostate cancer expression profiles of cytoplasmic ERbeta1 and nuclear ERbeta2 are associated with poor outcomes following radical prostatectomy.
    J Urol. 2016 Jan 21. pii: S0022-5347(16)00095-1. doi: 10.1016/j.juro.2015.
    PubMed     Text format     Abstract available


  270. ATALA A
    Re: Elf5 Inhibits TGF-beta-Driven Epithelial-Mesenchymal Transition in Prostate Cancer by Repressing SMAD3 Activation.
    J Urol. 2016;195:221.
    PubMed     Text format    


  271. PENSON DF
    Re: Course and Predictors of Cognitive Function in Patients with Prostate Cancer Receiving Androgen-Deprivation Therapy: A Controlled Comparison.
    J Urol. 2016;195:97.
    PubMed     Text format    


  272. TANEJA SS
    Re: Duration of Androgen Suppression before Radiotherapy for Localized Prostate Cancer: Radiation Therapy Oncology Group Randomized Clinical Trial 9910.
    J Urol. 2016;195:96.
    PubMed     Text format    


  273. SIEGEL C
    Re: Diagnosis of Extracapsular Extension of Prostate Cancer on Prostate MRI: Impact of Second-Opinion Readings by Subspecialized Genitourinary Oncologic Radiologists.
    J Urol. 2016;195:96-7.
    PubMed     Text format    


  274. TANEJA SS
    Re: A Genomic Classifier Improves Prediction of Metastatic Disease within 5 Years after Surgery in Node-Negative High-Risk Prostate Cancer Patients Managed by Radical Prostatectomy without Adjuvant Therapy.
    J Urol. 2016;195:95.
    PubMed     Text format    


  275. TANEJA SS
    Re: Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer.
    J Urol. 2016;195:94-6.
    PubMed     Text format    


  276. BANERJI JS, Wolff EM, Massman JD 3rd, Odem-Davis K, et al
    Prostate Needle Biopsy Outcomes in the Era of the U.S. Preventive Services Task Force Recommendation against Prostate Specific Antigen Based Screening.
    J Urol. 2016;195:66-73.
    PubMed     Text format     Abstract available


  277. LANZ C, Cornud F, Beuvon F, Lefevre A, et al
    Gleason Score Determination with Transrectal Ultrasound-Magnetic Resonance Imaging Fusion Guided Prostate Biopsies--Are We Gaining in Accuracy?
    J Urol. 2016;195:88-93.
    PubMed     Text format     Abstract available


    December 2015
  278. NATARAJAN S, Raman S, Priester AM, Garritano J, et al
    Focal Laser Ablation of Prostate Cancer: Phase I Clinical Trial.
    J Urol. 2015 Dec 31. pii: S0022-5347(15)05540-8. doi: 10.1016/j.juro.2015.
    PubMed     Text format     Abstract available


  279. ELSHAFEI A, Nyame Y, Kara O, Badawy A, et al
    More Favorable Pathological Outcomes in Men with Low-Risk Prostate Cancer Diagnosed on Repeat versus Initial Transrectal Ultrasound-Guided Prostate Biopsy.
    J Urol. 2015 Dec 24. pii: S0022-5347(15)05534-2. doi: 10.1016/j.juro.2015.
    PubMed     Text format     Abstract available


  280. MOSCHINI M, Sharma V, Zattoni F, Boorjian SA, et al
    Risk stratification of pN+ prostate cancer after radical prostatectomy from a large single institutional series with long-term follow-up.
    J Urol. 2015 Dec 23. pii: S0022-5347(15)05529-9. doi: 10.1016/j.juro.2015.
    PubMed     Text format     Abstract available


  281. YAMAMOTO T, Musunuru B, Vesprini D, Zhang L, et al
    Metastatic Prostate Cancer in Men Initially Managed with Active Surveillance.
    J Urol. 2015 Dec 17. pii: S0022-5347(15)05445-2. doi: 10.1016/j.juro.2015.
    PubMed     Text format     Abstract available


  282. WEINER AB, Conti RM, Eggener SE
    National economic conditions and patient insurance status predict prostate cancer diagnosis rates and management decisions.
    J Urol. 2015 Dec 17. pii: S0022-5347(15)05506-8. doi: 10.1016/j.juro.2015.
    PubMed     Text format     Abstract available


  283. LIBERMAN D, Jarosek S, Virnig BA, Chu H, et al
    The Patient Burden of Bladder Outlet Obstruction After Prostate Cancer Treatment.
    J Urol. 2015 Dec 9. pii: S0022-5347(15)05398-7. doi: 10.1016/j.juro.2015.
    PubMed     Text format     Abstract available


  284. MAURER T, Gschwend JE, Rauscher I, Souvatzoglou M, et al
    Diagnostic Efficacy of Gallium-PSMA-PET compared to Conventional Imaging in Lymph Node Staging of of 130 consecutive Patients with Intermediate to High-Risk Prostate Cancer.
    J Urol. 2015 Dec 9. pii: S0022-5347(15)05397-5. doi: 10.1016/j.juro.2015.
    PubMed     Text format     Abstract available


  285. XU M, Sakamoto S, Matsushima J, Kimura T, et al
    Upregulation of LAT1 during anti-androgen therapy contribute to progression in prostate cancer cells.
    J Urol. 2015 Dec 9. pii: S0022-5347(15)05395-1. doi: 10.1016/j.juro.2015.
    PubMed     Text format     Abstract available


  286. KIMURA T, Takahashi H, Okayasu M, Kido M, et al
    Time Trends in Histological Features of Latent Prostate Cancer in Japan.
    J Urol. 2015 Dec 8. pii: S0022-5347(15)05383-5. doi: 10.1016/j.juro.2015.
    PubMed     Text format     Abstract available


  287. GODTMAN RA, Carlsson S, Holmberg E, Stranne J, et al
    The effect of start and stop age at screening on the risk of being diagnosed with prostate cancer.
    J Urol. 2015 Dec 8. pii: S0022-5347(15)05364-1. doi: 10.1016/j.juro.2015.
    PubMed     Text format     Abstract available


  288. FELKER ER, Wu J, Natarajan S, Margolis DJ, et al
    Serial MRI in Active Surveillance of Prostate Cancer: Incremental Value.
    J Urol. 2015 Dec 7. pii: S0022-5347(15)05347-1. doi: 10.1016/j.juro.2015.
    PubMed     Text format     Abstract available


  289. SHEN X, Kumar P
    Trade-Off Between Treatment of Early Prostate Cancer and Incidence of Advanced Prostate Cancer in the Prostate Screening Era.
    J Urol. 2015 Dec 2. pii: S0022-5347(15)05348-3. doi: 10.1016/j.juro.2015.
    PubMed     Text format     Abstract available


  290. ATALA A
    Re: A Feedback Regulation between miR-145 and DNA Methyltransferase 3b in Prostate Cancer Cell and Their Responses to Irradiation.
    J Urol. 2015;194:1823-1824.
    PubMed     Text format    


  291. TANEJA SS
    Re: Adverse Pathology and Undetectable Ultrasensitive Prostate-Specific Antigen after Radical Prostatectomy: Is Adjuvant Radiation Warranted?
    J Urol. 2015;194:1631-2.
    PubMed     Text format    


  292. HUMPHREY PA
    Seminal Vesicle Invasion by Adenocarcinoma of the Prostate.
    J Urol. 2015;194:1757-8.
    PubMed     Text format    


  293. RENARD-PENNA R, Cancel-Tassin G, Comperat E, Varinot J, et al
    Multiparametric Magnetic Resonance Imaging Predicts Postoperative Pathology but Misses Aggressive Prostate Cancers as Assessed by Cell Cycle Progression Score.
    J Urol. 2015;194:1617-23.
    PubMed     Text format     Abstract available


  294. STATTIN K, Sandin F, Bratt O, Lambe M, et al
    The Risk of Distant Metastases and Cancer Specific Survival in Men with Serum Prostate Specific Antigen Values above 100 ng/ml.
    J Urol. 2015;194:1594-600.
    PubMed     Text format     Abstract available


  295. ZUMSTEG ZS, Spratt DE, Romesser PB, Pei X, et al
    Anatomical Patterns of Recurrence Following Biochemical Relapse in the Dose Escalation Era of External Beam Radiotherapy for Prostate Cancer.
    J Urol. 2015;194:1624-30.
    PubMed     Text format     Abstract available


  296. MENDHIRATTA N, Rosenkrantz AB, Meng X, Wysock JS, et al
    Magnetic Resonance Imaging-Ultrasound Fusion Targeted Prostate Biopsy in a Consecutive Cohort of Men with No Previous Biopsy: Reduction of Over Detection through Improved Risk Stratification.
    J Urol. 2015;194:1601-6.
    PubMed     Text format     Abstract available


  297. SEFTEL AD
    Re: Obesity and Hypogonadism Are Associated with an Increased Risk of Predominant Gleason 4 Pattern on Radical Prostatectomy Specimen.
    J Urol. 2015;194:1632-3.
    PubMed     Text format    


  298. TANEJA SS
    Re: Predicting High-Grade Cancer at Ten-Core Prostate Biopsy Using Four Kallikrein Markers Measured in Blood in the ProtecT Study.
    J Urol. 2015;194:1632.
    PubMed     Text format    



  299. Reply by Authors.
    J Urol. 2015;194:1826.
    PubMed     Text format    


    November 2015
  300. SCHELLHAMMER PF
    Re: Should the Urologist Treat Castration Resistant Prostate Cancer? Yes: M. P. Wirth and M. Froehner J Urol 2015;194:286.
    J Urol. 2015 Nov 27. pii: S0022-5347(15)04936-8. doi: 10.1016/j.juro.2015.
    PubMed     Text format    


  301. VALERIO M, Anele C, Bott SR, Charman SC, et al
    The prevalence of clinically significant prostate cancer according to commonly used histological thresholds in men undergoing template prostate mapping biopsies.
    J Urol. 2015 Nov 25. pii: S0022-5347(15)05318-5. doi: 10.1016/j.juro.2015.
    PubMed     Text format     Abstract available


  302. YU J, Kwon YS, Kim S, Han CS, et al
    Pathological Outcome Following Radical Prostatectomy in Men with PSA Greater than 10 and Histologically Favorable-Risk Prostate Cancer.
    J Urol. 2015 Nov 19. pii: S0022-5347(15)05249-0. doi: 10.1016/j.juro.2015.
    PubMed     Text format     Abstract available


  303. KAUFFMAN EC, Lee MJ, Alarcon SV, Lee S, et al
    Lack of impact of robotic-assisted laparoscopic radical prostatectomy on intraoperative levels of prostate cancer circulating tumor cells.
    J Urol. 2015 Nov 12. pii: S0022-5347(15)05227-1. doi: 10.1016/j.juro.2015.
    PubMed     Text format     Abstract available


  304. AMINI A, Jones B, Jackson MW, Yeh N, et al
    Survival Outcomes of Dose-Escalated External Beam Radiotherapy (DE-EBRT) Versus Combined Brachytherapy for Intermediate- and High-Risk Prostate Cancer Using the National Cancer Data Base.
    J Urol. 2015 Nov 11. pii: S0022-5347(15)05217-9. doi: 10.1016/j.juro.2015.
    PubMed     Text format     Abstract available


  305. SANDLER H
    Reply by Author.
    J Urol. 2015;194:1508-9.
    PubMed     Text format    


  306. HOPPE B
    Reply by Author.
    J Urol. 2015;194:1508.
    PubMed     Text format    


  307. HUMPHREY PA
    Intraductal Carcinoma of the Prostate.
    J Urol. 2015;194:1434-5.
    PubMed     Text format    


  308. BRYK DJ, Llukani E, Huang WC, Lepor H, et al
    Natural History of Pathologically Benign Cancer Suspicious Regions on Multiparametric Magnetic Resonance Imaging Following Targeted Biopsy.
    J Urol. 2015;194:1234-40.
    PubMed     Text format     Abstract available


  309. HAWKEN SR, Womble PR, Herrel LA, Ye Z, et al
    Understanding the Performance of Active Surveillance Selection Criteria in Diverse Urology Practices.
    J Urol. 2015;194:1253-7.
    PubMed     Text format     Abstract available


    October 2015
  310. ATALA A
    Re: The Inhibitor of Differentiation Isoform Id1b, Generated by Alternative Splicing, Maintains Cell Quiescence and Confers Self-Renewal and Cancer Stem Cell-Like Properties.
    J Urol. 2015;194:1163.
    PubMed     Text format    


  311. CHANG SS
    Re: Metastases in Normal-Sized Pelvic Lymph Nodes: Detection with Diffusion-Weighted MR Imaging.
    J Urol. 2015;194:954-5.
    PubMed     Text format    


  312. EMBERTON M
    Why Focal Therapy is a Legitimate and Necessary Response to a Changing World.
    J Urol. 2015;194:875-6.
    PubMed     Text format    


    September 2015
  313. SEFTEL AD
    Re: Urinary Incontinence and Erectile Dysfunction after Robotic versus Open Radical Prostatectomy: A Prospective, Controlled, Nonrandomised Trial.
    J Urol. 2015;194:706.
    PubMed     Text format    


    June 2015
  314. ATALA A
    Re: Identification and Characterization of Membrane Androgen Receptors in the ZIP9 Zinc Transporter Subfamily: II. Role of Human ZIP9 in Testosterone-Induced Prostate and Breast Cancer Cell Apoptosis.
    J Urol. 2015;193:2147.
    PubMed     Text format    


  315. ATALA A
    Re: Tumour-infiltrating Gr-1+ myeloid cells antagonize senescence in cancer.
    J Urol. 2015;193:2146.
    PubMed     Text format    


  316. CADEDDU JA
    Re: A multinational, multi-institutional study comparing positive surgical margin rates among 22393 open, laparoscopic, and robot-assisted radical prostatectomy patients.
    J Urol. 2015;193:1984-5.
    PubMed     Text format    


  317. TANEJA SS
    Re: The relationship between the extent of extraprostatic extension and survival following radical prostatectomy.
    J Urol. 2015;193:1982.
    PubMed     Text format    


  318. BABAYAN RK
    Re: Examining the relationship between operative time and hospitalization time in minimally invasive and open urologic procedures.
    J Urol. 2015;193:1930.
    PubMed     Text format    


Thank you for your interest in scientific medicine.


AMEDEO Prostate Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: